改善非小细胞肺癌结局:根治性放疗的最佳剂量分割至关重要
该研究分析英国国家放疗数据集,比较55 Gy/20次(2.75 Gy/次)与60-66 Gy/30-33次(2 Gy/次)两种方案。在169,863例NSCLC中,I-III期接受根治性放疗者占17%-18%。校正预后因素后,2.75 Gy/次组中位生存25个月,2 Gy/次组为29个月(队列1 HR=1.16,p=0.001;队列2 HR=1.10,p=0.02)。作者认为常规分割应继续作为标准治疗。
要点
- 英国2012-2016年NSCLC数据中,I-III期仅17%-18%接受根治性放疗。
- 队列1中2.75 Gy/次组中位生存25个月,2 Gy/次组29个月(HR=1.16,p=0.001)。
- 队列2中2.75 Gy/次组中位生存25个月,2 Gy/次组28个月(HR=1.10,p=0.02)。
核心结论
- 对英国全国NSCLC队列的大数据分析提示,与4周方案55 Gy/20次相比,6周常规每日分割60-66 Gy、2 Gy/次与生存获益相关。
- 在回顾性大数据分析存在潜在选择偏倚且缺乏随机试验的局限下,结果提示常规分割方案应继续作为标准治疗。
研究设计与样本
- 分析英国公共卫生署登记的2012年1月至2016年12月169,863例NSCLC病例,分为2012-2013年诊断的队列1(训练集)和2014-2016年诊断的队列2(验证集)。
- 放疗数据来自国家放疗数据集,通过国家健康服务号码链接国家统计局生存数据和医院 Episode 统计,从中获取手术数据和Charlson合并症指数。
- 73,186例I-III期NSCLC中12,898例接受根治性分割放疗(队列1为4,894例,队列2为8,004例)。
- 采用比例风险模型分析从诊断起的总体生存,校正年龄、性别、分期、合并症、其他根治性治疗和辅助化疗等预后因素,以风险比(HR)和95%置信区间总结方案差异,用对数似然检验评估差异显著性。
主要发现
- I-III期NSCLC患者中17%至18%接受根治性分割放疗。
- 校正年龄、分期、合并症及其他根治性和辅助治疗等独立预后因素后,队列1中接受2.75 Gy/次方案的患者中位生存25个月,接受2 Gy/次方案的患者为29个月(HR=1.16,p=0.001)。
- 队列2中,2.75 Gy/次方案与2 Gy/次方案的中位生存分别为25个月和28个月(HR=1.10,p=0.02)。
关键数值与推荐
- 比较方案为最常用的中等大分割方案55 Gy/20次(2.75 Gy/次)与常规分割方案60-66 Gy/30-33次(2 Gy/次)。
- 队列1:2.75 Gy/次组中位生存25个月 vs 2 Gy/次组29个月(HR=1.16,p=0.001)。
- 队列2:2.75 Gy/次组中位生存25个月 vs 2 Gy/次组28个月(HR=1.10,p=0.02)。
临床怎么用
- 作者结论认为,常规分割方案应继续作为标准治疗。
局限性
- 原文指出该分析为回顾性大数据分析,存在潜在选择偏倚。
- 原文指出缺乏随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We analyzed a comprehensive national radiotherapy data set to compare outcomes of the most frequently used moderate hypofractionation regimen (55 Gy in 20 fractions) and conventional fractionation regimen (60-66 Gy in 30-33 fractions). METHODS: A total of 169,863 cases of NSCLC registered in England from January 2012 to December 2016 obtained from the Public Health England were divided into cohort 1 (training set) diagnosed in 2012 to 2013 and cohort 2 (validation set) diagnosed in 2014 to 2016. Radiotherapy data were obtained from the National Radiotherapy Dataset and linked by National Health Service number to survival data from the Office of National Statistics and Hospital Episode Statistics, from which surgical data and Charlson comorbidity index were obtained. Of 73,186 patients with stages I to III NSCLC, 12,898 received radical fractionated radiotherapy (cohort 1-4894; cohort 2-8004). The proportional hazards model was used to investigate overall survival from time of diagnosis. Survival was adjusted for the prognostic factors of age, sex, stage of disease, comorbidity, other radical treatments, and adjuvant chemotherapy, and the difference between the treatment schedules was summarized by hazard ratio (HR) and 95% confidence interval. The significance of any difference was evaluated by the log likelihood test. RESULTS: Of patients with stages I to III NSCLC, 17% to 18% received radical fractionated radiotherapy. After adjustment for independent prognostic factors of age, stage, comorbidity, and other radical and adjuvant treatments, patients in cohort 1 treated with the 2.75 Gy per fraction regimen had a median survival of 25 months compared with 29 months for patients treated with the 2 Gy per fraction regimen (HR = 1.16, p = 0.001). Similarly, in cohort 2, the respective median survival values were 25 and 28 months (HR = 1.10, p = 0.02). CONCLUSIONS: Big data analysis of a comprehensive national cohort of patients with NSCLC treated in England suggests that compared with a 4-week regimen of 55 Gy in 20 fractions, a 6-week regimen of conventional daily fractionation to a dose of 60 to 66 Gy at 2 Gy per fraction is associated with a survival benefit. Within the limitations of the retrospective big data analysis with potential selection bias and in the absence of randomized trials, the results suggest that conventional fractionation regimens should remain the standard of care.
引用
- Brada M, Forbes H, Ashley S, et al. Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters. J Thorac Oncol. 2022. PMID: 35092841. doi:10.1016/j.jtho.2022.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。